Pharmacology
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
GLP1
+1
Jun 6, 2026
•
7 min read
GLP-1 Resistance Is Real. You Probably Don’t Have It.
A genetic study just caught true GLP-1 resistance in the act. Almost no one being called a “non-responder” fits the description.
GLP1
+1
May 23, 2026
•
9 min read
The Accidental Hormone.
A century-long hunt for a phantom gut hormone, a peptide chemist written out of the story, and a venomous desert lizard. Here is where Ozempic actually comes from — and who actually found it.
GLP1
+2
May 19, 2026
•
13 min read
ECO 2026: The Maintenance Era Begins.
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.
CV
+3
Apr 15, 2026
•
16 min read
Statins Don't Cause What You Think They Cause. Except When They Do.
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.
GLP1
+3
Mar 27, 2026
•
15 min read
What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.
